Submitted by Anonymous (not verified) on 27 September 2023 - 13:36
Human medicines European public assessment report (EPAR): Glyxambi, empagliflozin,linagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 11/11/2016, Revision: 16, Status: Authorised
Source: